Aclaris Therapeutics (ACRS) Common Equity (2014 - 2026)

Aclaris Therapeutics' Common Equity history runs 13 years deep, the most recent figure standing at $143.6 million for Q1 2026.

• In Q1 2026, Common Equity changed 0.29% year-over-year to $143.6 million; the TTM figure through Mar 2026 stood at $143.6 million (changed 0.29% YoY), while the FY2025 annual figure was $103.1 million, down 33.73% from the prior year.
• Common Equity for Q1 2026 stood at $143.6 million, up from $103.1 million in the prior quarter.
• The five-year high for Common Equity was $235.8 million in Q2 2022, with the low at $103.1 million in Q4 2025.
• The 5-year median for Common Equity is $155.6 million (2024), against an average of $159.3 million.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 60.47% in 2022, then plunged 33.73% in 2025.
• Aclaris Therapeutics' Common Equity stood at $197.6 million in 2022, then slipped by 20.46% to $157.2 million in 2023, then fell by 1.03% to $155.6 million in 2024, then sank by 33.73% to $103.1 million in 2025, then surged by 39.35% to $143.6 million in 2026.
• Business Quant data shows ACRS's Common Equity at $143.6 million in Q1 2026, $103.1 million in Q4 2025, and $120.1 million in Q3 2025.